JP7773466B2 - Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質 - Google Patents

Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質

Info

Publication number
JP7773466B2
JP7773466B2 JP2022530837A JP2022530837A JP7773466B2 JP 7773466 B2 JP7773466 B2 JP 7773466B2 JP 2022530837 A JP2022530837 A JP 2022530837A JP 2022530837 A JP2022530837 A JP 2022530837A JP 7773466 B2 JP7773466 B2 JP 7773466B2
Authority
JP
Japan
Prior art keywords
bcma
antibody
binding
cancer
fit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022530837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504016A5 (cg-RX-API-DMAC7.html
JP2023504016A (ja
Inventor
ウー、チョンビン
ウー、タンチン
ホアン、リニ
チャン、アミン
ショアイ、チョンロン
チャン、ルイ
コン、シヨン
ウー、シュアン
Original Assignee
シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド filed Critical シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド
Publication of JP2023504016A publication Critical patent/JP2023504016A/ja
Publication of JP2023504016A5 publication Critical patent/JP2023504016A5/ja
Priority to JP2024185441A priority Critical patent/JP7847630B2/ja
Application granted granted Critical
Publication of JP7773466B2 publication Critical patent/JP7773466B2/ja
Priority to JP2026063021A priority patent/JP2026108862A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022530837A 2019-11-26 2020-11-26 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質 Active JP7773466B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024185441A JP7847630B2 (ja) 2019-11-26 2024-10-21 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
JP2026063021A JP2026108862A (ja) 2019-11-26 2026-04-07 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019120991 2019-11-26
CNPCT/CN2019/120991 2019-11-26
CN2020111796 2020-08-27
CNPCT/CN2020/111796 2020-08-27
PCT/CN2020/131767 WO2021104371A1 (en) 2019-11-26 2020-11-26 Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024185441A Division JP7847630B2 (ja) 2019-11-26 2024-10-21 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質

Publications (3)

Publication Number Publication Date
JP2023504016A JP2023504016A (ja) 2023-02-01
JP2023504016A5 JP2023504016A5 (cg-RX-API-DMAC7.html) 2023-12-01
JP7773466B2 true JP7773466B2 (ja) 2025-11-19

Family

ID=76130007

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022530837A Active JP7773466B2 (ja) 2019-11-26 2020-11-26 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
JP2024185441A Active JP7847630B2 (ja) 2019-11-26 2024-10-21 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
JP2026063021A Pending JP2026108862A (ja) 2019-11-26 2026-04-07 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024185441A Active JP7847630B2 (ja) 2019-11-26 2024-10-21 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
JP2026063021A Pending JP2026108862A (ja) 2019-11-26 2026-04-07 Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質

Country Status (11)

Country Link
US (1) US20230002489A1 (cg-RX-API-DMAC7.html)
EP (2) EP4065164A4 (cg-RX-API-DMAC7.html)
JP (3) JP7773466B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240162588A (cg-RX-API-DMAC7.html)
CN (1) CN114728065A (cg-RX-API-DMAC7.html)
AU (2) AU2020390288A1 (cg-RX-API-DMAC7.html)
CA (1) CA3160163A1 (cg-RX-API-DMAC7.html)
IL (2) IL293138A (cg-RX-API-DMAC7.html)
MX (2) MX2022006230A (cg-RX-API-DMAC7.html)
TW (1) TWI774137B (cg-RX-API-DMAC7.html)
WO (1) WO2021104371A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
IL300760A (en) * 2020-08-24 2023-04-01 Epimab Biotherapeutics Hk Ltd Anti-ROR1 antibodies and related bispecific binding proteins
US20250051443A1 (en) * 2021-10-07 2025-02-13 National Research Council Of Canada Anti-cd3 monoclonal antibodies and therapeutic constructs
CN116375868A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
CN117003871A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
WO2024012513A1 (en) * 2022-07-13 2024-01-18 Hansoh Bio Llc Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用
CN120418284A (zh) * 2022-12-19 2025-08-01 和铂医药(上海)有限责任公司 “κ/λ” Fab-Fab串联多特异性结合蛋白及其制备和应用
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117024596B (zh) * 2023-08-18 2024-02-27 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025131077A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3多特异性抗体及用途
WO2025168059A1 (zh) * 2024-02-08 2025-08-14 天劢源和生物医药(上海)有限公司 靶向bcma、cd19和cd3的多特异性抗原结合蛋白及其应用
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504314A (ja) 2013-12-17 2017-02-09 ジェネンテック, インコーポレイテッド 抗cd3抗体および使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Bcmaに対する抗体の選択のための方法
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
EP3310811B1 (en) * 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
JP7014724B2 (ja) * 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Fab免疫グロブリンおよびその使用
IL299221A (en) * 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CA3032430A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
CN109535257B (zh) * 2017-09-22 2021-05-28 同润生物医药(上海)有限公司 新型双特异性cd3/cd19多肽复合物
EP3732199A1 (en) * 2017-12-27 2020-11-04 TeneoBio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
CN112074541A (zh) * 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504314A (ja) 2013-12-17 2017-02-09 ジェネンテック, インコーポレイテッド 抗cd3抗体および使用方法

Also Published As

Publication number Publication date
IL293138A (en) 2022-07-01
JP7847630B2 (ja) 2026-04-17
MX2024013229A (es) 2024-12-06
AU2024278367A1 (en) 2025-01-09
TW202132347A (zh) 2021-09-01
EP4065164A1 (en) 2022-10-05
EP4483895A2 (en) 2025-01-01
CA3160163A1 (en) 2021-06-03
US20230002489A1 (en) 2023-01-05
JP2026108862A (ja) 2026-06-30
AU2020390288A1 (en) 2022-05-26
JP2025011311A (ja) 2025-01-23
MX2022006230A (es) 2022-06-22
CN114728065A (zh) 2022-07-08
EP4483895A3 (en) 2025-05-28
KR20240162588A (ko) 2024-11-15
JP2023504016A (ja) 2023-02-01
TWI774137B (zh) 2022-08-11
WO2021104371A1 (en) 2021-06-03
KR20220104783A (ko) 2022-07-26
IL316618A (en) 2024-12-01
EP4065164A4 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
JP7847630B2 (ja) Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
TWI907489B (zh) 抗ror1抗體及相關雙特異性結合蛋白
KR20160127825A (ko) 항-mcam 항체 및 관련된 사용 방법
KR20160131061A (ko) 항-mcam 항체 및 관련된 사용 방법
TW202041537A (zh) 針對lag-3之工程化抗體及自其製備之雙特異性pd-1/lag-3結合蛋白
JP2024054284A (ja) ガンの処置のための結合分子
TW202035448A (zh) 有效表現之egfr及pd-l1雙特異性結合蛋白
US20250282881A1 (en) Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
RU2852663C1 (ru) Антитела против cd3 и bcma и биспецифичные связывающие белки, полученные из них
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
WO2022228545A1 (en) Antibodies and variants thereof against human 4-1bb
BR122025002178A2 (pt) Anticorpos para cd3 e bcma, e proteínas de ligação biespecíficas feitas a partir dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251107

R150 Certificate of patent or registration of utility model

Ref document number: 7773466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150